Article
Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22).
European journal of haematology - 1 Oct 2002
Seftel M D, Bruyere H, Copland M, Hogge D E, Horsman D E, Nantel S H, Shepherd J D, Lavoie J C, Le A, Sutherland H J, Toze C L, Nevill T J
Abstract excerpt
Tumour lysis syndrome (TLS) is caused by rapid breakdown of malignant cells resulting in electrolyte disturbances and acute renal failure. TLS has rarely been described in patients with acute myelogenous leukaemia (AML). Between November 1997 and July 2001, 114 consecutive adult AML patients aged <60 yr received induction chemotherapy consisting of cytosine arabinoside 1.5 g m(-2) q 12 h x 12 doses and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
